🔥 Absolute masterclass @philseo in the Clinical Year in Review #ACR23 ➡️ Certain subpopulations have lower risk of AE with Tofacitinib ➡️ Knee OA 📈 75% by 2050 ➡️ Exciting novel approaches in Rx of IA in development ➡️Better clinical trial endpoints needed for SLE https://t.co/5cjbZLPsCM

Phase 2 RCT of TLL-018 (JAK1/TYK2i) vs Tofa in RA. 101 patients. ACR50 72% vs 42%. 83% of tofa-IR achieved ACR50 on TLL-018. Can't wait for the phase 3 data! Abstr#0840 #ACR23 @RheumNow #ACRbest https://t.co/wjGx4Edxyb https://t.co/n6CL8G01Wo

TLL-018, the dual JAK1/Tyk2 inhibitor which caused all the chatter at #EULAR2023, now with more full data showing it absolutely smash tofacitinib in RA, with similar safety. “This is a spectacular compound - unbelievably spectacular” - Roy Fleischmann #ACR23 ABST0840 @RheumNow https://t.co/nIKQb4yYrJ

More on TLL-018 How? A: Everyone surprised. But maybe dual mech benefits re: pain via IFN Where’s the multinational RCT in RA? A: Priority on rapid registration in China, quickly. But ph2 trials for psoriasis happening in US, results so far look consistent. #ACR23 @RheumNow

Fascinating how upadacitinib may well have an effect on pain in RA, beyond inflammation. Now seen similar for bari in RA & guselkumab in PsA. And, if real, for some people could be a massive get. Love to see dedicated studies SELECT-COMPARE post-hoc #ACR23 ABST0429 @RheumNow https://t.co/Tk278mGJYY

Ab#0596 #ACR23 @RheumNow R Furie on Decravacitinib in SLE 48wk double-blind trial. PBO v DEU 3mgBID, 6 mgBID,12 mg qd Higher response, faster time to SRI(4), BICLA and dual response v PBO. More likely to sustain response from w32-48. https://t.co/M34d3nQmwv

Abs#518 @RheumNow #ACR23 Deodhar: TOFA in AS, by b/l CRP levels 30% nml CRP (<5 mg/L) v 70% Elevated At wk 12, TOFA >> PBO regardless of b/l CRP Difference in response: greater in pts w elevated CRP Safety rates: elev. CRP c/w PBO, but nml CRP had trend of high AEs for tofa v PBO https://t.co/b9NRNkU8ub